Efficacy of 25-hydroxyvitamin D3 in colon cancer chemoprevention
Efficacy of 25-hydroxyvitamin D3 in colon cancer chemoprevention
批准号:
7795762
负责人:
RAJENDRA G MEHTA
金额:
$37.49万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-07-05 至 2012-05-31
关键词:
Aberrant crypt fociAdenocarcinomaAnimalsAzoxymethaneCalcifediolCalcitriolCancer ModelCarcinogensCell LineChemopreventive AgentCholecalciferolClinicalColonColon CarcinomaColonic NeoplasmsColorectal CancerDataDevelopmentDietDietary intakeDistalDoseEnzymesEpidemiologyEpithelial CellsExposure toGenus ColaHormonesHumanHypercalcemiaIncidenceIntakeKnock-outKnockout MiceKnowledgeLaboratoriesMediatingMixed Function OxygenasesModelingMusMutatePharmaceutical PreparationsPlasmaPolypsPreventionPrevention therapyRelative (related person)Research PersonnelRiskRoleSerumSignal PathwaySignal TransductionSunlightToxic effectTumor BurdenUp-RegulationVitamin DVitamin D AnalogVitamin D3 ReceptorVitaminsWomananalogcancer cellcancer chemopreventioncarcinogenesiscolon cancer cell linecolon carcinogenesiscolorectal cancer preventiondesignin vivoinhibitor/antagonistnovelpreventreceptor expressionresearch studyresponsetumor progression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The role of vitamin D in colorectal cancer (CRC) prevention is well recognized. Epidemiological evidence demonstrates an inverse relationship between vitamin D, both dietary intake and exposure to sunlight, and risk of developing colon cancer. Similarly, decreased plasma levels of 25-hydroxyvitamin D3 [25(OH)D3] have been shown to correlate with increased polyp formation in distal colons of women. Experimental evidence has found that treatment of animals with the active metabolite of vitamin D, 1,25-dihydroxyvitamin D3, reduces colon tumor burden. However, 1,25(OH)2D3 causes hypercalcemia. In view of this numerous analogs of vitamin D have been synthesized. Yet only a handful of these analogs have been successfully used for the prevention and therapy of colon cancer. In our laboratory we synthesized a novel vitamin D analog, 1a-hydroxy-24-ethyl-cholecalciferol [1cc(OH)D5]. The preliminary results showed that this agent at non-toxic levels significantly decreases the formation of aberrant crypt foci (ACF) by 85% in mice exposed to the carcinogen azoxymethane (AOM). Recently, it has been observed that 1a-hydroxylase, required to convert non-toxic 25(OH)D3 to 1,25(OH)2D3- is present in colonic epithelial cells. This suggests that 25(OH)D3 alone may serve as potential chemopreventive agent. Finally, the role of vitamin D receptor (VDR) remains to be fully elucidated. Our preliminary data indicates that vitamin D's role in CRC chemopreventive activity requires VDR expression, and that aberrant (3Jcatenin may be modified by up- regulation of VDR. Thus, we hypothesize that 25(OH)D3 will serve as a colon chemopreventive agent with its actions mediated primarily via VDR. Our specific aims are to: (1 A) Determine the dose response of 25(OH)D3 in suppressing the development of AOM-induced ACF and adenocarcinomas in CF-1 mice; (1B) Evaluate the relative efficacy of 25(OH)D3, 1a(OH)D5, and 1,25(OH)2D3 in colon carcinogenesis. For this aim the AOM-induced CRC model will be used; (2) Assess the role VDR, 1a(OH)ase, and 24-hydroxylase in ACF and CRC progression. For these studies an AOM-induced carcinogenesis model using VDR knockout and their wild-type counterparts will be used to evaluate the responsiveness to 25(OH)D3; and (3) Investigate the mediating role of VDR in the wnt/(3-catenin signaling pathway and its relation to vitamin D actions. The studies will provide a rationale for using 25(OH)D3 for the prevention of colon carcinogenesis.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Deguelin in therapy of triple negative breast cancer
-
批准号:8403823
-
项目类别:
-
资助金额:$43.88万
-
财政年份:2011
-
负责人:RAJENDRA G MEHTA
-
依托单位:
Deguelin in therapy of triple negative breast cancer
-
批准号:8594137
-
项目类别:
-
资助金额:$45.38万
-
财政年份:2011
-
负责人:RAJENDRA G MEHTA
-
依托单位:
Deguelin in therapy of triple negative breast cancer
-
批准号:8041345
-
项目类别:
-
资助金额:$46.49万
-
财政年份:2011
-
负责人:RAJENDRA G MEHTA
-
依托单位:
Deguelin in therapy of triple negative breast cancer
-
批准号:8206749
-
项目类别:
-
资助金额:$46.59万
-
财政年份:2011
-
负责人:RAJENDRA G MEHTA
-
依托单位:
Efficacy of 25-hydroxyvitamin D3 in colon cancer chemoprevention
-
批准号:7313152
-
项目类别:
-
资助金额:$37.49万
-
财政年份:2007
-
负责人:RAJENDRA G MEHTA
-
依托单位:
Efficacy of 25-hydroxyvitamin D3 in colon cancer chemoprevention
-
批准号:7624959
-
项目类别:
-
资助金额:$37.49万
-
财政年份:2007
-
负责人:RAJENDRA G MEHTA
-
依托单位:
Efficacy of 25-hydroxyvitamin D3 in colon cancer chemoprevention
-
批准号:7460854
-
项目类别:
-
资助金额:$37.49万
-
财政年份:2007
-
负责人:RAJENDRA G MEHTA
-
依托单位:
CORE--MOUSE MAMMARY ORGAN CULTURE
-
批准号:6563828
-
项目类别:
-
资助金额:$22.84万
-
财政年份:2002
-
负责人:RAJENDRA G MEHTA
-
依托单位:
CORE--MOUSE MAMMARY ORGAN CULTURE
-
批准号:6444601
-
项目类别:
-
资助金额:$22.84万
-
财政年份:2001
-
负责人:RAJENDRA G MEHTA
-
依托单位:
VITAMIN D5 IN PREVENTION OF MAMMARY CARCINOGENSIS
-
批准号:6129475
-
项目类别:
-
资助金额:$16.79万
-
财政年份:2000
-
负责人:RAJENDRA G MEHTA
-
依托单位:
EVAUATION OF CHEMOPREVENTIVE AGENTS BY IN VITRO SCREENIN
-
批准号:6346790
-
项目类别:
-
资助金额:$21.26万
-
财政年份:2000
-
负责人:RAJENDRA G MEHTA
-
依托单位:
CORE--MOUSE MAMMARY ORGAN CULTURE
-
批准号:6300331
-
项目类别:
-
资助金额:$17.72万
-
财政年份:2000
-
负责人:RAJENDRA G MEHTA
-
依托单位:
VITAMIN D5 IN PREVENTION OF MAMMARY CARCINOGENSIS
-
批准号:6514062
-
项目类别:
-
资助金额:$17.82万
-
财政年份:2000
-
负责人:RAJENDRA G MEHTA
-
依托单位:
Vitamin D5 in Prevention of Mammary Carcinogenesis
-
批准号:6802724
-
项目类别:
-
资助金额:$29.78万
-
财政年份:2000
-
负责人:RAJENDRA G MEHTA
-
依托单位:
VITAMIN D5 IN PREVENTION OF MAMMARY CARCINOGENSIS
-
批准号:6377331
-
项目类别:
-
资助金额:$17.3万
-
财政年份:2000
-
负责人:RAJENDRA G MEHTA
-
依托单位:
Vitamin D5 in Prevention of Mammary Carcinogenesis
-
批准号:6950440
-
项目类别:
-
资助金额:$30.14万
-
财政年份:2000
-
负责人:RAJENDRA G MEHTA
-
依托单位:
Vitamin D5 in Prevention of Mammary Carcinogenesis
-
批准号:7119932
-
项目类别:
-
资助金额:$30.13万
-
财政年份:2000
-
负责人:RAJENDRA G MEHTA
-
依托单位:
Vitamin D5 in Prevention of Mammary Carcinogenesis
-
批准号:6679359
-
项目类别:
-
资助金额:$20.17万
-
财政年份:2000
-
负责人:RAJENDRA G MEHTA
-
依托单位:
IN VITRO SCREENING OF CHEMOPREVENTIVE AGENTS IN DMBA-IND
-
批准号:6130160
-
项目类别:
-
资助金额:$0.0万
-
财政年份:1999
-
负责人:RAJENDRA G MEHTA
-
依托单位:
IN VITRO SCREENING OF CHEMOPREVENTIVE AGENTS IN DMBA-IND
-
批准号:6129525
-
项目类别:
-
资助金额:$24.24万
-
财政年份:1999
-
负责人:RAJENDRA G MEHTA
-
依托单位:
国内基金
海外基金
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
-
批准号:30840003
-
项目类别:专项基金项目
-
资助金额:12.0万元
-
批准年份:2008
-
负责人:焦宇飞
-
依托单位: